Clinical Trial

Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

Study acronym: SQI-01-03
Completed Phase 1
View on ClinicalTrials.gov →
Summary
The trial is to compare the bioavailability of the original European Lasix (furosemide injection) administered in accordance with its prescribing information with the same dose of a novel furosemide formulation developed for this subcutaneous administration. The study will also investigate PK and PD of these regimens.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-25; most recent amendment 2026-04-21.
Status change: Not Yet Recruiting → Completed 2026-03-16
Trial Details
NCT Number NCT07269496
Lead Sponsor SQ Innovation, Inc.
Collaborators: BDD Pharma Ltd
Conditions Healthy
Enrollment 16 participants
Start Date 2026-02-09
Primary Completion 2026-03-09 (estimated)
Study Completion 2026-03-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-22